The Clinical Study of Personalized Therapy for Non-small Cell Lung Cancer Based on ERCC1/RRM1/TS/β-Tubulin Expression
Patients who had nonsmall cell lung cancer (NSCLC) performance status of 0/1 were accrued to
2 phase 2 clinical trials Trial A (carboplatin and chemotherapy individuation based on
sensitivity marker ), Trial B (carboplatin non-individuation or chemotherapy
Patients who were treated on Trials B were analyzed as the "standard therapy" group.
Patients accrued to Trial A were called the "personalized therapy" group. Overall survival
(OS), disease free survival (DFS) and progression-free survival (PFS) were estimated using
the Kaplan-Meier method.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
progression-free survival of Patients
From treatment beginning,Patients will be followed for up to 2 years.
up to 2 years
Jianxing He, Proressor
The first affiliated hospital of Guangzhou MC
United States: Food and Drug Administration